Cancer Letters
Volume 294, Issue 2 , Pages 236-244 , 28 August 2010

Overexpression of LAPTM4B-35 promotes growth and metastasis of hepatocellular carcinoma in vitro and in vivo

  • Hua Yang

      Affiliations

    • Department of Cell Biology, School of Basic Medical Sciences, Peking University, Beijing 100191, China
    • These authors contributed equally to this work.
    • ,
  • Fuxia Xiong

      Affiliations

    • Department of Cell Biology, School of Basic Medical Sciences, Peking University, Beijing 100191, China
    • These authors contributed equally to this work.
    • ,
  • Xuanhui Wei

      Affiliations

    • Department of Cell Biology, School of Basic Medical Sciences, Peking University, Beijing 100191, China
    • ,
  • Yu Yang

      Affiliations

    • Department of Pathology, School of Basic Medical Sciences, Peking University, Beijing, China
    • ,
  • Michael A. McNutt

      Affiliations

    • Department of Pathology, School of Basic Medical Sciences, Peking University, Beijing, China
    • ,
  • Rouli Zhou

      Affiliations

    • Department of Cell Biology, School of Basic Medical Sciences, Peking University, Beijing 100191, China
    • Corresponding Author InformationCorresponding author. Tel.: +86 10 82801468; fax: +86 10 6235 8270.

Received 16 December 2009 ,Revised 5 February 2010 ,Accepted 10 February 2010.

References 

  1. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003;362:1907–1917
  2. Bosch FX, Ribes J, Cleries R, Diaz M. Epidemiology of hepatocellular carcinoma. Clin. Liver Dis. 2005;9:191–211
  3. Thorgeirsson SS, Grisham JW. Molecular pathogenesis of human hepatocellular carcinoma. Nat. Genet. 2002;31:339–346
  4. Llovet JM, Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology. 2008;48:1312–1327
  5. Garcia-Echeverria C, Sellers WR. Drug discovery approaches targeting the PI3K/Akt pathway in cancer. Oncogene. 2008;27:5511–5526
  6. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat. Rev. Cancer. 2002;2:489–501
  7. Adjei AA, Hidalgo M. Treating cancer by blocking cell signals. J. Clin. Oncol. 2005;23:5279–5280
  8. Jung YJ, Lee KH, Choi DW, Han CJ, Jeong SH, Kim KC, et al. Reciprocal expressions of cyclin E and cyclin D1 in hepatocellular carcinoma. Cancer Lett. 2001;168:57–63
  9. Liu X, Zhou R, Zhang Q, Zhang Y, Shao G, Jin Y, et al. Identification and characterization of LAPTM4B encoded by a human hepatocellular carcinoma-associated novel gene. Beijing Da Xue Xue Bao. 2003;35:340–347
  10. Yang H, Xiong FX, Lin M, Yang Y, Nie X, Zhou RL. LAPTM4B-35 overexpression is a risk factor for tumor recurrence and poor prognosis in hepatocellular carcinoma. J. Cancer Res. Clin. Oncol. 2010;136:275–281
  11. Singer S, Ehemann V, Brauckhoff A, Keith M, Vreden S, Schirmacher P, et al. Protumorigenic overexpression of stathmin/Op18 by gain-of-function mutation in p53 in human hepatocarcinogenesis. Hepatology. 2007;46:759–768
  12. Kleinman HK, McGarvey ML, Hassell JR, Star VL, Cannon FB, Laurie GW, et al. Basement membrane complexes with biological activity. Biochemistry. 1986;25:312–318
  13. Albini A, Iwamoto Y, Kleinman HK, Martin GR, Aaronson SA, Kozlowski JM, et al. A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res. 1987;47:3239–3245
  14. Yeh E, Cunningham M, Arnold H, Chasse D, Monteith T, Ivaldi G, et al. A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells. Nat. Cell Biol. 2004;6:308–318
  15. Canner JA, Sobo M, Ball S, Hutzen B, DeAngelis S, Willis W, et al. MI-63: a novel small-molecule inhibitor targets MDM2 and induces apoptosis in embryonal and alveolar rhabdomyosarcoma cells with wild-type p53. Brit. J. Cancer. 2009;101:774–781
  16. Daksis JI, Lu RY, Facchini LM, Marhin WW, Penn LJ. Myc induces cyclin D1 expression in the absence of de novo protein synthesis and links mitogen-stimulated signal transduction to the cell cycle. Oncogene. 1994;9:3635–3645
  17. Cantley LC. The phosphoinositide 3-kinase pathway. Science. 2002;296:1655–1657
  18. Diehl JA, Cheng M, Roussel MF, Sherr CJ. Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev. 1998;12:3499–3511
  19. Sears R, Nuckolls F, Haura E, Taya Y, Tamai K, Nevins JR. Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. Genes Dev. 2000;14:2501–2514
  20. Medema RH, Kops GJ, Bos JL, Burgering BM. AFX-like forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1. Nature. 2000;404:782–787
  21. Peng C, Zhou RL, Shao GZ, Rui JA, Wang SB, Lin M, et al. Expression of lysosome-associated protein transmembrane 4B-35 in cancer and its correlation with the differentiation status of hepatocellular carcinoma. World J. Gastroenterol. 2005;11:2704–2708
  22. Inoue S. Cyclin and cell cycle. Gan To Kagaku Ryoho. 1997;24:909–918
  23. Pelengaris S, Khan M, Evan GI. Suppression of Myc-induced apoptosis in beta cells exposes multiple oncogenic properties of Myc and triggers carcinogenic progression. Cell. 2002;109:321–334
  24. Eisenman RN. Deconstructing myc. Genes Dev. 2001;15:2023–2030
  25. Perez-Roger I, Solomon DL, Sewing A, Land H. Myc activation of cyclin E/Cdk2 kinase involves induction of cyclin E gene transcription and inhibition of p27(Kip1) binding to newly formed complexes. Oncogene. 1997;14:2373–2381
  26. Amati B, Alevizopoulos K, Vlach J. Myc and the cell cycle. Front. Biosci. 1998;3:d250–268
  27. Junttila MR, Westermarck J. Mechanisms of MYC stabilization in human malignancies. Cell Cycle. 2008;7:592–596
  28. Obsil T, Ghirlando R, Anderson DE, Hickman AB, Dyda F. Two 14-3-3 binding motifs are required for stable association of forkhead transcription factor FOXO4 with 14-3-3 proteins and inhibition of DNA binding. Biochemistry. 2003;42:15264–15272
  29. Fiorentino M, Altimari A, D’Errico A, Cukor B, Barozzi C, Loda M, et al. Acquired expression of p27 is a favorable prognostic indicator in patients with hepatocellular carcinoma. Clin. Cancer Res. 2000;6:3966–3972

PII: S0304-3835(10)00094-7

doi: 10.1016/j.canlet.2010.02.006

Cancer Letters
Volume 294, Issue 2 , Pages 236-244 , 28 August 2010

Article Tools

* Image Usage & Resolution